- Trials with a EudraCT protocol (7)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
7 result(s) found for: Nerve ending.
Displaying page 1 of 1.
| EudraCT Number: 2014-005656-26 | Sponsor Protocol Number: 51748.094.15 | Start Date*: 2015-10-14 | ||||||||||||||||
| Sponsor Name:Westfriesgasthuis | ||||||||||||||||||
| Full Title: Amitriptyline 10% and ketamine 10% cream in neuropathic pain: A randomised, double-blind, placebo-controlled cross-over pilot study with a three months open follow-up | ||||||||||||||||||
| Medical condition: Patients with peripheral neuropathic pain or scar pain | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: NL (Ongoing) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2015-000636-15 | Sponsor Protocol Number: 12/201/02 | Start Date*: 2015-05-27 |
| Sponsor Name:Bangor University | ||
| Full Title: A randomised controlled trial of adalimumab injection compared with placebo for patients receiving physiotherapy treatment for sciatica. | ||
| Medical condition: Sciatica is a symptom defined as unilateral, well-localised leg pain, with a sharp, shooting or burning quality, that approximates to the dermatomal distribution of the sciatic nerve down the poste... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: GB (Prematurely Ended) | ||
| Trial results: View results | ||
| EudraCT Number: 2015-000287-34 | Sponsor Protocol Number: ARO-012 | Start Date*: 2017-05-30 | |||||||||||
| Sponsor Name:Arog Pharmaceuticals, Inc. | |||||||||||||
| Full Title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Trial of Crenolanib in Subjects with Advanced or Metastatic Gastrointestinal Stromal Tumors with a D842V Mutation in the PDGFRA Gene. | |||||||||||||
| Medical condition: Advanced or metastatic gastrointestinal stromal tumor (GIST) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Ongoing) ES (Ongoing) GB (GB - no longer in EU/EEA) IT (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2014-001549-26 | Sponsor Protocol Number: TRASTS | Start Date*: 2014-11-03 |
| Sponsor Name:GEIS | ||
| Full Title: Phase I-II prospective trial, multicenter, open label, exploring the combination of Trabectedin plus Radiotherapy in Soft Tissue Sarcoma patients. | ||
| Medical condition: Soft Tissue Sarcoma | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: ES (Ongoing) IT (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2021-001186-20 | Sponsor Protocol Number: GEIS-83 | Start Date*: 2021-10-22 |
| Sponsor Name:GRUPO ESPAÑOL DE INVESTIGACIÓN EN SARCOMAS | ||
| Full Title: Phase Ib/II multicohort trial of different schemes of PM14 in monotherapy and in combination with radiotherapy in soft tissue sarcomas and other solid tumors | ||
| Medical condition: Advanced soft tissue sarcoma and other solid tumors | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: ES (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2008-008922-55 | Sponsor Protocol Number: GEIS20 | Start Date*: 2009-06-04 | |||||||||||
| Sponsor Name:Grupo Español de Investigación en Sarcomas | |||||||||||||
| Full Title: ENSAYO FASE II ALEATORIZADO, ABIERTO, MULTICÉNTRICO Y PROSPECTIVO DE DOXORRUBICINA vs TRABECTEDINA Y DOXORRUBICINA EN PRIMERA LÍNEA DE PACIENTES CON SARCOMA DE PARTES BLANDAS AVANZADOS NO OPERABLES... | |||||||||||||
| Medical condition: Sarcoma de partes blandas avanzados no operables y/o metastásicos | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Prematurely Ended) PT (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2022-003050-32 | Sponsor Protocol Number: FAB122-CT-2201 | Start Date*: 2023-02-21 |
| Sponsor Name:Ferrer Internacional S.A. | ||
| Full Title: A multicenter, open-label extension study to investigate the long-term safety of FAB122 in patients with Amyotrophic Lateral Sclerosis | ||
| Medical condition: Amyotrophic Lateral Sclerosis (ALS) | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: IT (Prematurely Ended) PL (Prematurely Ended) DE (Completed) SE (Completed) BE (Completed) ES (Completed) PT (Prematurely Ended) | ||
| Trial results: (No results available) | ||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.